Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 5/2009

01-05-2009 | Review and Perspective

Mitochondria and cancer

Authors: Valdemar Máximo, Jorge Lima, Paula Soares, Manuel Sobrinho-Simões

Published in: Virchows Archiv | Issue 5/2009

Login to get access

Abstract

The authors review the role played by mutations in mitochondrial DNA and in nuclear genes encoding mitochondrial proteins in cancer development, with an emphasis on the alterations of the oxidative phosphorylation system and glycolysis.
Literature
1.
2.
Warburg O (1930) The metabolism of tumours. London Constable, London
3.
Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530CrossRefPubMed
4.
Baysal BE, Ferrell RE, Willett-Brozick JE et al (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848–851PubMedCrossRef
5.
Astuti D, Latif F, Dallol A et al (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49–54PubMedCrossRef
6.
Niemann S, Muller U (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26:268–270PubMedCrossRef
7.
Horvath R, Abicht A, Holinski-Feder E et al (2006) Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). J Neurol Neurosurg Psychiatry 77:74–76PubMedCrossRef
8.
9.
Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39:359–407PubMedCrossRef
10.
Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332PubMedCrossRef
11.
Habano W, Sugai T, Nakamura SI et al (2000) Microsatellite instability and mutation of mitochondrial and nuclear DNA in gastric carcinoma. Gastroenterology 118:835–841PubMedCrossRef
12.
Richard SM, Bailliet G, Paez GL et al (2000) Nuclear and mitochondrial genome instability in human breast cancer. Cancer Res 60:4231–4237PubMed
13.
Maximo V, Soares P, Seruca R et al (2001) Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. Genes Chromosomes Cancer 32:136–143PubMedCrossRef
14.
Burgart LJ, Zheng J, Shu Q et al (1995) Somatic mitochondrial mutation in gastric cancer. Am J Pathol 147:1105–1111PubMed
15.
Habano W, Sugai T, Yoshida T et al (1999) Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability. Int J Cancer 83:625–629PubMedCrossRef
16.
Polyak K, Li Y, Zhu H et al (1998) Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 20:291–293PubMedCrossRef
17.
Fliss MS, Usadel H, Caballero OL et al (2000) Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287:2017–2019PubMedCrossRef
18.
Yeh JJ, Lunetta KL, Van Orsouw NJ et al (2000) Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 19:2060–2066PubMedCrossRef
19.
Lewis PD, Baxter P, Paul GA et al (2000) Detection of damage to the mitochondrial genome in the oncocytic cells of Warthin's tumour. J Pathol 191:274–281PubMedCrossRef
20.
Tallini G, Ladanyi M, Rosai J et al (1994) Analysis of nuclear and mitochondrial DNA alterations in thyroid and renal oncocytic tumors. Cytogenet Cell Genet 66:253–259PubMedCrossRef
21.
Maximo V, Soares P, Lima J et al (2002) Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 160:1857–1865PubMed
22.
Abu-Amero KK, Alzahrani AS, Zou M et al (2005) High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines. Oncogene 24:1455–1460PubMedCrossRef
23.
Bonora E, Porcelli AM, Gasparre G et al (2006) Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 66:6087–6096PubMedCrossRef
24.
Lohrer HD, Hieber L, Zitzelsberger H (2002) Differential mutation frequency in mitochondrial DNA from thyroid tumours. Carcinogenesis 23:1577–1582PubMedCrossRef
25.
Maximo V, Sobrinho-Simoes M (2000) Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 437:107–115PubMedCrossRef
26.
Maximo V, Lima J, Soares P et al (2005) Mitochondrial D-loop instability in thyroid tumours is not a marker of malignancy. Mitochondrion 5:333–340PubMedCrossRef
27.
Rogounovitch T, Saenko V, Yamashita S (2004) Mitochondrial DNA and human thyroid diseases. Endocr J 51:265–277PubMedCrossRef
28.
Savagner F, Franc B, Guyetant S et al (2001) Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors. J Clin Endocrinol Metab 86:4920–4925PubMedCrossRef
29.
Gasparre G, Porcelli AM, Bonora E et al (2007) Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A 104:9001–9006PubMedCrossRef
30.
Gasparre G, Iommarini L, Porcelli AM et al (2008) An inherited mitochondrial DNA disruptive mutation shifts to homoplasmy in oncocytic tumor cells. Hum Mutat 30:391–396CrossRef
31.
Jeronimo C, Nomoto S, Caballero OL et al (2001) Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 20:5195–5198PubMedCrossRef
32.
Zhou S, Kachhap S, Sun W et al (2007) Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A 104:7540–7545PubMedCrossRef
33.
Park JS, Sharma LK, Li HZ et al. (2009) A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet (in press)
34.
Lima J, Maximo V, Soares P et al (2009) Mitochondria and oncocytomas. In: Singh KK, Costello LC (eds) Mitochondria and cancer. Springer, New York, pp 193–209CrossRef
35.
Copeland WC, Wachsman JT, Johnson FM et al (2002) Mitochondrial DNA alterations in cancer. Cancer Invest 20:557–569PubMedCrossRef
36.
Czarnecka AM, Golik P, Bartnik E (2006) Mitochondrial DNA mutations in human neoplasia. J Appl Genet 47:67–78PubMed
37.
Tamori A, Nishiguchi S, Nishikawa M et al (2004) Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma. J Gastroenterol 39:1063–1068PubMedCrossRef
38.
Petros JA, Baumann AK, Ruiz-Pesini E et al (2005) mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 102:719–724PubMedCrossRef
39.
Shidara Y, Yamagata K, Kanamori T et al (2005) Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res 65:1655–1663PubMedCrossRef
40.
Pelicano H, Xu RH, Du M et al (2006) Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 175:913–923PubMedCrossRef
41.
Gottlieb E, Tomlinson IP (2005) Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5:857–866PubMedCrossRef
42.
Lima J, Teixeira-Gomes J, Soares P et al (2003) Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. J Clin Endocrinol Metab 88:4932–4937PubMedCrossRef
43.
Montani M, Schmitt AM, Schmid S et al (2005) No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. Endocr Relat Cancer 12:1011–1016PubMedCrossRef
44.
Cascon A, Cebrian A, Pollan M et al (2005) Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 90:2127–2130PubMedCrossRef
45.
Ricketts C, Woodward ER, Killick P et al (2008) Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 100:1260–1262PubMedCrossRef
46.
Tomlinson IP, Alam NA, Rowan AJ et al (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406–410PubMedCrossRef
47.
Eng C, Kiuru M, Fernandez MJ et al (2003) A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 3:193–202PubMedCrossRef
48.
Pollard PJ, Briere JJ, Alam NA et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231–2239PubMedCrossRef
49.
Maximo V, Botelho T, Capela J et al (2005) Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 92:1892–1898PubMedCrossRef
50.
Huang G, Lu H, Hao A et al (2004) GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol Cell Biol 24:8447–8456PubMedCrossRef
51.
Alchanati I, Nallar SC, Sun P et al (2006) A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 25:7138–7147PubMedCrossRef
52.
53.
Ramanathan A, Wang C, Schreiber SL (2005) Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A 102:5992–5997PubMedCrossRef
54.
Matoba S, Kang JG, Patino WD et al (2006) p53 regulates mitochondrial respiration. Science 312:1650–1653PubMedCrossRef
55.
Kaelin WG Jr, Ratcliffe PJ (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30:393–402PubMedCrossRef
56.
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899PubMedCrossRef
57.
Ishikawa K, Takenaga K, Akimoto M et al (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320:661–664PubMedCrossRef
58.
Piruat JI, Pintado CO, Ortega-Saenz P et al (2004) The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia. Mol Cell Biol 24:10933–10940PubMedCrossRef
59.
Muller-Hocker J (1992) Random cytochrome-C-oxidase deficiency of oxyphil cell nodules in the parathyroid gland. A mitochondrial cytopathy related to cell ageing? Pathol Res Pract 188:701–706PubMed
60.
Rosai J, Carcangiu ML, DeLellis RA (1992) Tumours of the thyroid gland. Armed Force Institute of Pathology, Washington, DC
61.
Sobrinho-Simoes MA, Nesland JM, Holm R et al (1985) Hurthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study. Ultrastruct Pathol 8:131–142PubMedCrossRef
62.
Nesland JM, Sobrinho-Simoes MA, Holm R et al (1985) Hurthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry. Ultrastruct Pathol 8:269–290PubMedCrossRef
63.
Ebner D, Rodel G, Pavenstaedt I et al (1991) Functional and molecular analysis of mitochondria in thyroid oncocytoma. Virchows Arch B Cell Pathol Incl Mol Pathol 60:139–144PubMedCrossRef
64.
Muller-Hocker J, Jacob U, Seibel P (1998) Hashimoto thyroiditis is associated with defects of cytochrome-c oxidase in oxyphil Askanazy cells and with the common deletion (4, 977) of mitochondrial DNA. Ultrastruct Pathol 22:91–100PubMed
65.
Ortmann M, Vierbuchen M, Koller G et al (1988) Renal oncocytoma. I. Cytochrome c oxidase in normal and neoplastic renal tissue as detected by immunohistochemistry—a valuable aid to distinguish oncocytomas from renal cell carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 56:165–173PubMedCrossRef
66.
Muller-Hocker J (2000) Expression of bcl-2, Bax and Fas in oxyphil cells of Hashimoto thyroiditis. Virchows Arch 436:602–607PubMedCrossRef
67.
Muller-Hocker J, Aust D, Napiwotzky J et al (1996) Defects of the respiratory chain in oxyphil and chief cells of the normal parathyroid and in hyperfunction. Hum Pathol 27:532–541PubMedCrossRef
68.
Cheung CC, Ezzat S, Ramyar L et al (2000) Molecular basis off Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85:878–882PubMedCrossRef
69.
Sobrinho-Simoes M, Maximo V, Castro IV et al (2005) Hurthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol 13:29–35PubMedCrossRef
70.
Langhans T (1907) Über die epithelialen Formen der malignen Struma. Virchows Arch 189:69–153CrossRef
71.
DeLellis RA LR, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine glands. IARC, Lyon
72.
Dominguez-Malagon H, Delgado-Chavez R, Torres-Najera M et al (1989) Oxyphil and squamous variants of medullary thyroid carcinoma. Cancer 63:1183–1188PubMedCrossRef
73.
Volante M, La Rosa S, Castellano I et al (2006) Clinico-pathological features of a series of 11 oncocytic endocrine tumours of the pancreas. Virchows Arch 448:545–551PubMedCrossRef
74.
Moran CA, Suster S (2000) Primary neuroendocrine carcinoma (thymic carcinoid) of the thymus with prominent oncocytic features: a clinicopathologic study of 22 cases. Mod Pathol 13:489–494PubMedCrossRef
75.
Baloch ZW, LiVolsi VA (1999) Oncocytic lesions of the neuroendocrine system. Semin Diagn Pathol 16:190–199PubMed
76.
77.
Soares P, Trovisco V, Rocha AS et al (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578–4580PubMedCrossRef
78.
Castro P, Rebocho AP, Soares RJ et al (2006) PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213–220PubMedCrossRef
79.
Trovisco V, Vieira DCI, Soares P et al (2004) BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202:247–251PubMedCrossRef
80.
Trovisco V, Soares P, Preto A et al (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446:589–595PubMedCrossRef
81.
Carcangiu ML, Bianchi S, Savino D et al (1991) Follicular Hurthle cell tumors of the thyroid gland. Cancer 68:1944–1953PubMedCrossRef
82.
Evans HL, Vassilopoulou-Sellin R (1998) Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. Am J Surg Pathol 22:1512–1520PubMedCrossRef
83.
McDonald MP, Sanders LE, Silverman ML et al (1996) Hurthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery 120:1000–1004PubMedCrossRef
84.
Papotti M, Botto Micca F, Favero A et al (1993) Poorly differentiated thyroid carcinomas with primordial cell component. A group of aggressive lesions sharing insular, trabecular, and solid patterns. Am J Surg Pathol 17:291–301PubMedCrossRef
85.
Watson RG, Brennan MD, Goellner JR et al (1984) Invasive Hurthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc 59:851–855PubMed
86.
Lang W, Choritz H, Hundeshagen H (1986) Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol 10:246–255PubMedCrossRef
87.
Valenta LJ, Michel-Bechet M, Warshaw JB et al (1974) Human thyroid tumors composed of mitochondrion-rich cells: electron microscopic and biochemical findings. J Clin Endocrinol Metab 39:719–733PubMedCrossRef
88.
Apel RL, Asa SL (2002) The parathyroid glands. In: LiVolsi V, Asa SL (eds) Endocrine pathology. Churchill Livingstone, Philadelphia, pp 103–137
89.
Giorgadze T, Stratton B, Baloch ZW et al (2004) Oncocytic parathyroid adenoma: problem in cytological diagnosis. Diagn Cytopathol 31:276–280PubMedCrossRef
90.
Erickson LA, Jin L, Papotti M et al (2002) Oxyphil parathyroid carcinomas: a clinicopathologic and immunohistochemical study of 10 cases. Am J Surg Pathol 26:344–349PubMedCrossRef
91.
Yoo GH, Eisele DW, Askin FB et al (1994) Warthin's tumor: a 40-year experience at The Johns Hopkins Hospital. Laryngoscope 104:799–803PubMedCrossRef
92.
Honda K, Kashima K, Daa T et al (2000) Clonal analysis of the epithelial component of Warthin's tumor. Hum Pathol 31:1377–1380PubMedCrossRef
93.
Kotwall CA (1992) Smoking as an etiologic factor in the development of Warthin's tumor of the parotid gland. Am J Surg 164:646–647PubMedCrossRef
94.
Zambrano NR, Lubensky IA, Merino MJ et al (1999) Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 162:1246–1258PubMedCrossRef
95.
Kuroda N, Toi M, Hiroi M et al (2003) Review of renal oncocytoma with focus on clinical and pathobiological aspects. Histol Histopathol 18:935–942PubMed
96.
Maximo V, Soares P, Rocha AS et al (1998) The common deletion of mitochondrial DNA is found in goiters and thyroid tumors with and without oxyphil cell change. Ultrastruct Pathol 22:271–273PubMedCrossRef
97.
Maximo V, Sobrinho-Simoes M (2000) Mitochondrial DNA ‘common’ deletion in Hurthle cell lesions of the thyroid. J Pathol 192:561–562PubMedCrossRef
98.
Attardi G, Yoneda M, Chomyn A (1995) Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. Biochim Biophys Acta 1271:241–248PubMed
99.
Heddi A, Faure-Vigny H, Wallace DC et al (1996) Coordinate expression of nuclear and mitochondrial genes involved in energy production in carcinoma and oncocytoma. Biochim Biophys Acta 1316:203–209PubMed
100.
Welter C, Kovacs G, Seitz G et al (1989) Alteration of mitochondrial DNA in human oncocytomas. Genes Chromosomes Cancer 1:79–82PubMedCrossRef
101.
Brooks JD, Marshall FF, Isaacs WB et al (1999) Absence of HinfI restriction abnormalities in renal oncocytoma mitochondrial DNA. Mol Urol 3:1–3PubMed
102.
Simonnet H, Alazard N, Pfeiffer K et al (2002) Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23:759–768PubMedCrossRef
103.
Simonnet H, Demont J, Pfeiffer K et al (2003) Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 24:1461–1466PubMedCrossRef
104.
Mayr JA, Meierhofer D, Zimmermann F et al (2008) Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res 14:2270–2275PubMedCrossRef
105.
Savagner F, Chevrollier A, Loiseau D et al (2001) Mitochondrial activity in XTC.UC1 cells derived from thyroid oncocytoma. Thyroid 11:327–333PubMedCrossRef
106.
Baris O, Savagner F, Nasser V et al (2004) Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab 89:994–1005PubMedCrossRef
107.
Jacques C, Baris O, Prunier-Mirebeau D et al (2005) Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab 90:2314–2320PubMedCrossRef
108.
Maximo V, Preto A, Crespo A et al (2004) Core I gene is overexpressed in Hurthle and non-Hurthle cell microfollicular adenomas and follicular carcinomas of the thyroid. BMC Cancer 4:12PubMedCrossRef
109.
Sobrinho-Simoes M, Preto A, Rocha AS et al (2005) Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 447:787–793PubMedCrossRef
110.
Pedersen PL (2007) Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the “Warburg effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39:211–222PubMedCrossRef
111.
Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83–91PubMedCrossRef
112.
Geschwind JF, Ko YH, Torbenson MS et al (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909–3913PubMed
113.
Bonnet S, Archer SL, Allalunis-Turner J et al (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37–51PubMedCrossRef
114.
Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270PubMed
115.
Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437–443PubMedCrossRef
116.
Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180–192PubMedCrossRef
117.
Higgins DF, Kimura K, Bernhardt WM et al (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117:3810–3820PubMed
118.
Yang MH, Wu MZ, Chiou SH et al (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10:295–305PubMedCrossRef
119.
120.
Selak MA, Armour SM, MacKenzie ED et al (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7:77–85PubMedCrossRef
121.
Metadata
Title
Mitochondria and cancer
Authors
Valdemar Máximo
Jorge Lima
Paula Soares
Manuel Sobrinho-Simões
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 5/2009
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-009-0766-2

Other articles of this Issue 5/2009

Virchows Archiv 5/2009 Go to the issue

Original Article

Transcription factors Snail, Slug, Twist, and SIP1 in spindle cell carcinoma of the head and neck

Original Article

Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer

Original Article

Intraosseous lymphocytic infiltrates after hip resurfacing arthroplasty

Original Article

Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology

Case Report

Biliary intraductal papillary mucinous neoplasia: three case reports

Original Article

Unison or cacophony: postgraduate training in pathology in Europe